Clinical trial NCT06667700: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Official title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Coronavirus Disease (COVID-19)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2024-10-31
Enrollment: 3082
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect.

Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.


Eligibility criteria: Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

* Is an individual of any sex/gender, ≥18 years of age
* Has documentation of SARS-CoV-2 infection with sample collection ≤4 days prior to randomization
* Has initial onset of signs/symptoms attributable to COVID-19 for ≤4 days prior to the day of randomization and ≥2 of the following signs/symptoms attributable to COVID-19 on the day of randomization: cough, sore throat, nasal congestion, shortness of breath or difficulty breathing with exertion, muscle or body aches, fatigue, fever \>38.0°C or chills, nausea or vomiting or diarrhea, change in sense of smell or change in sense of taste, or headache
* Has ≥1 of the following characteristics or medical conditions associated with the highest risk of severe illness from COVID-19:

  * Advanced age of ≥75 years of age
  * Immunocompromised
  * Neurocognitive or physical disability
* Has ≥3 characteristics or medical conditions which increase the risk of severe illness due to COVID-19 (e.g., chronic lung disease, obesity with body mass index ≥35, diabetes)
* Is unable to receive treatment with nirmatrelvir/ritonavir (NMV/r) due to 1 or more of the following:

  * Is receiving drug(s) highly dependent on cytochrome P450 3A (CYP3A) for clearance and for which elevated concentrations are associated with serious and/or life-threatening consequences or drug(s) with a clinically significant drug-drug interaction for which co-administration is not possible
  * Is receiving potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance
  * Has severe renal or hepatic impairment
  * Has experienced prior adverse reactions or hepatotoxicity to NMV/r that would preclude future use
  * Has uncontrolled HIV infection
  * Has known or suspected NMV/r resistance
  * NMV/r is not approved/authorized in the participant's country or it is not accessible to participant (e.g., drug shortage)

Inclusion note: Participants may receive remdesivir as standard of care in addition to molnupiravir or placebo. If remdesivir is available and clinically appropriate per local clinical practice, investigators will aim to ensure that those who are most vulnerable to severe COVID-19 receive timely access to remdesivir as standard of care on this study.

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

* Is currently hospitalized or is expected to need hospitalization for COVID-19 imminently
* Has received or plans to receive SARS-CoV-2 directed antivirals or monoclonal antibodies for current episode of COVID-19 (other than study intervention and, if applicable, remdesivir as standard of care)
* Has ≥1 of the following signs/symptoms that are attributable to severe or critical COVID-19:

  * Shortness of breath at rest
  * Respiratory rate ≥30 breaths per minute
  * Heart rate ≥125 beats per minute
  * Peripheral oxygen saturation (SpO2) ≤93% on room air or on supplemental oxygen for a reason other than COVID-19 which has not increased since onset of COVID-19 signs/symptoms
  * Is receiving \>4 liters/minute supplemental oxygen for COVID-19 (but was not receiving supplemental oxygen prior to COVID-19), regardless of SpO2
* Has received a COVID-19 vaccine within 30 days prior to randomization
* Has a history of SARS-CoV-2 infection (with or without symptoms) within 30 days prior to randomization
* Has known or suspected hypersensitivity to active or inactive ingredients of molnupiravir

Primary outcomes:
measure: Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization, All-cause Mortality, or Covid-19-related Medically-attended Visit (MAV)
timeFrame: Up to 29 days
measure: Percentage of Participants Who Experience an Adverse Event (AE)
timeFrame: Up to approximately 5 months
measure: Percentage of Participants Who Discontinue Study Intervention Due to AE
timeFrame: Up to approximately 5 days
Secondary outcomes:
measure: Time to Sustained Alleviation Without Relapse of All 8 Selected COVID-19-related Signs/Symptoms Through Day 29
timeFrame: Up to 29 days
measure: Change from Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load
timeFrame: Day 1 (baseline) and up to Day 29
measure: Percentage of Participants with Undetectable SARS-CoV-2 Viral Load
timeFrame: Up to 29 days
measure: Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization or All-cause Mortality
timeFrame: Up to 29 days
measure: Percentage of Participants With Clinically Important Medical Interventions (CIMI) Associated with COVID-19-related MAV or COVID-19-related Hospitalization Through Day 29
timeFrame: Up to 29 days
measure: Time to Sustained Alleviation Without Relapse of All 15 COVID-19-related Signs/Symptoms Through Day 29
timeFrame: Up to 29 days
measure: Time to Sustained Resolution Without Relapse of All 8 Selected COVID-19-related Signs/Symptoms Through Day 29
timeFrame: Up to 29 days
Other outcomes:
Locations:
city: Cullman
country: United States
facility: Cullman Clinical Trials ( Site 3813)
state: Alabama
city: Paradise Valley
country: United States
facility: Helios Clinical Research ( Site 3826)
state: Arizona
city: Phoenix
country: United States
facility: Absolute Clinical Research ( Site 3709)
state: Arizona
city: Castroville
country: United States
facility: Clinica de Salud del Valle de Salinas ( Site 3825)
state: California
city: Fullerton
country: United States
facility: Ascada Health PC dba Ascada Research ( Site 3750)
state: California
city: Los Alamitos
country: United States
facility: Pacific Clinical Studies ( Site 3827)
state: California
city: Northridge
country: United States
facility: Valley Clinical Trials, Inc. ( Site 3707)
state: California
city: Oxnard
country: United States
facility: FOMAT Medical Research ( Site 3720)
state: California
city: San Diego
country: United States
facility: Paradigm Clinical Research, LLC ( Site 3785)
state: California
city: San Francisco
country: United States
facility: Optimus Medical ( Site 3817)
state: California
city: Westlake Village
country: United States
facility: Millennium Clinical Trials ( Site 3758)
state: California
city: Wheat Ridge
country: United States
facility: Paradigm Clinical Research Centers, Inc ( Site 3718)
state: Colorado
city: Boynton Beach
country: United States
facility: Encore Medical Research of Boynton Beach ( Site 3701)
state: Florida
city: Coral Gables
country: United States
facility: Prestige Clinical Research Center ( Site 3722)
state: Florida
city: Hialeah
country: United States
facility: Indago Research & Health Center, Inc ( Site 3714)
state: Florida
city: Homestead
country: United States
facility: Prestige Clinical Research ( Site 3830)
state: Florida
city: Largo
country: United States
facility: Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779)
state: Florida
city: Leesburg
country: United States
facility: Clinical Site Partners, LLC dba Flourish Research ( Site 3717)
state: Florida
city: Loxahatchee Groves
country: United States
facility: Advanced Pulmonary Research Institute ( Site 3781)
state: Florida
city: Miami Lakes
country: United States
facility: Palm Springs Community Health Center ( Site 3757)
state: Florida
city: Miami Lakes
country: United States
facility: Panax Clinical Research ( Site 3803)
state: Florida
city: Miami
country: United States
facility: Southern Clinical Research ( Site 3773)
state: Florida
city: Miami
country: United States
facility: Florida Pharmaceutical Research and Associates ( Site 3763)
state: Florida
city: Miami
country: United States
facility: Bio-Medical Research LLC ( Site 3804)
state: Florida
city: Miami
country: United States
facility: Bright Research Center ( Site 3746)
state: Florida
city: Miami
country: United States
facility: Miami Clinical Research ( Site 3729)
state: Florida
city: Miami
country: United States
facility: Reed Medical Research ( Site 3761)
state: Florida
city: Orlando
country: United States
facility: Combined Research Orlando Phase I-IV ( Site 3797)
state: Florida
city: Port Saint Lucie
country: United States
facility: CDC Research Institute ( Site 3716)
state: Florida
city: Tampa
country: United States
facility: New Tampa Health ( Site 3764)
state: Florida
city: Tampa
country: United States
facility: Clinical Research Trials of Florida ( Site 3703)
state: Florida
city: Tampa
country: United States
facility: Precision Research Center ( Site 3704)
state: Florida
city: Weston
country: United States
facility: Encore Medical Research - Weston ( Site 3708)
state: Florida
city: Lawrenceville
country: United States
facility: Balanced Life Health Care Solutions/SKYCRNG ( Site 3713)
state: Georgia
city: Snellville
country: United States
facility: Renew Health Clinical Research ( Site 3760)
state: Georgia
city: Union City
country: United States
facility: Rophe Adult and Pediatric Medicine/SKYCRNG ( Site 3816)
state: Georgia
city: Boise
country: United States
facility: Paradigm Clinical Research - Boise ( Site 3841)
state: Idaho
city: Louisville
country: United States
facility: University of Louisville School of Medicine ( Site 3706)
state: Kentucky
city: Natchitoches
country: United States
facility: Barnum Medical Research ( Site 3828)
state: Louisiana
city: Annapolis
country: United States
facility: Annapolis Internal Medicine - CCT Research ( Site 3700)
state: Maryland
city: Columbia
country: United States
facility: Kur Research - Columbia Medical ( Site 3767)
state: Maryland
city: Dearborn
country: United States
facility: Revival Research Institute, LLC ( Site 3835)
state: Michigan
city: Farmington Hills
country: United States
facility: Michigan Center of Medical Research (MICHMER) ( Site 3734)
state: Michigan
city: Grosse Pointe Woods
country: United States
facility: Henry Ford St John TM Center for Infectious Disease Research ( Site 3766)
state: Michigan
city: Mankato
country: United States
facility: Mankato Clinic ( Site 3842)
state: Minnesota
city: Fayette
country: United States
facility: Prime Health and Wellness/SKYCRNG ( Site 3726)
state: Mississippi
city: Ridgeland
country: United States
facility: SKY Integrative Medical Center/SKYCRNG ( Site 3740)
state: Mississippi
city: Carson City
country: United States
facility: Nevada Health Centers ( Site 3840)
state: Nevada
city: Las Vegas
country: United States
facility: WR-CRCN, LLC ( Site 3818)
state: Nevada
city: Teaneck
country: United States
facility: Holy Name Medical Center ( Site 3807)
state: New Jersey
city: Bronx
country: United States
facility: Prime Global Research ( Site 3731)
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College ( Site 3814)
state: New York
city: Charlotte
country: United States
facility: OnSite Clinical Solutions ( Site 3784)
state: North Carolina
city: Monroe
country: United States
facility: Monroe Biomedical Research ( Site 3732)
state: North Carolina
city: Mount Airy
country: United States
facility: IMA Clinical Research Mount Airy ( Site 3745)
state: North Carolina
city: Beavercreek
country: United States
facility: Research Innovations, LLC ( Site 3712)
state: Ohio
city: Columbia
country: United States
facility: Midlands Neurology & Pain Associates ( Site 3751)
state: South Carolina
city: Jackson
country: United States
facility: Helios Clinical Research - JAC ( Site 3833)
state: Tennessee
city: Conroe
country: United States
facility: Javara - Privia Medical Group Gulf Coast - The Woodlands HWH ( Site 3837)
state: Texas
city: Corpus Christi
country: United States
facility: South Texas Clinical Research ( Site 3815)
state: Texas
city: Forney
country: United States
facility: Care United Research, LLC ( Site 3747)
state: Texas
city: Laredo
country: United States
facility: Andres Garcia Zuniga, M.D., P.A. ( Site 3782)
state: Texas
city: Pearland
country: United States
facility: LinQ Research ( Site 3824)
state: Texas
city: Victoria
country: United States
facility: Crossroads Clinical Research-Family Practice ( Site 3739)
state: Texas
city: Hampton
country: United States
facility: Velocity Clinical Research - Hampton ( Site 3744)
state: Virginia
city: Redmond
country: United States
facility: Eastside Research Associates ( Site 3727)
state: Washington
city: Buenos Aires.
country: Argentina
facility: CEMIC ( Site 0101)
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires.
country: Argentina
facility: Hospital Italiano de Buenos Aires ( Site 0107)
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Instituto de Investigaciones Clinicas Mar del Plata ( Site 0111)
state: Buenos Aires
city: Morón
country: Argentina
facility: Nefra Medical Care - Moron ( Site 0109)
state: Buenos Aires
city: Kozloduy
country: Bulgaria
facility: Medical Center Zdrave 1 ( Site 0509)
state: Vratsa
city: Lovech
country: Bulgaria
facility: Medconsult Pleven - Lovech ( Site 0501)
city: Montana
country: Bulgaria
facility: Medical Center Hera ( Site 0507)
city: Pleven
country: Bulgaria
facility: Medconsult Pleven ( Site 0503)
city: Plovdiv
country: Bulgaria
facility: DKC V - Plovdiv ( Site 0508)
city: Sofia
country: Bulgaria
facility: Diagnostic Consultative Center 22 - Sofia ( Site 0500)
city: Sofia
country: Bulgaria
facility: Medical Center Hera EOOD ( Site 0505)
city: Helsinki
country: Finland
facility: MeVac - Meilahti Vaccine Research Center ( Site 1200)
state: Uusimaa
city: Dijon
country: France
facility: Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-Centre d'Investigation Clinique - Plur ( Site 1301)
state: Bourgogne
city: Paris
country: France
facility: Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 1300)
state: Ile-de-France
city: Saint Priest en Jarez
country: France
facility: CHU de Saint-Etienne ( Site 1302)
state: Loire
city: Pierre-Bénite
country: France
facility: centre hospitalier lyon sud ( Site 1303)
state: Rhone
city: Batumi
country: Georgia
facility: Family Medical Regional Center ( Site 1404)
state: Ajaria
city: Batumi
country: Georgia
facility: University Clinic of Innovative Medicine ( Site 1400)
state: Ajaria
city: Tbilisi
country: Georgia
facility: Curatio Clinic - Main Location ( Site 1401)
city: Munchen
country: Germany
facility: klinikum rechts der isar der technischen universität münchen ( Site 1502)
state: Bayern
city: Berlín
country: Germany
facility: Campus Charite Mitte Nephrologie und Internistische Intensivmedizin ( Site 1501)
state: Berlin
city: Frankfurt
country: Germany
facility: Universitätsklinikum Frankfurt Goethe-Universität ( Site 1503)
state: Hessen
city: Köln
country: Germany
facility: Universitaetsklinikum Koeln ( Site 1505)
state: Nordrhein-Westfalen
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1904)
city: Genova
country: Italy
facility: Ospedale San Martino ( Site 1900)
city: Milano
country: Italy
facility: ASST Fatebenefratelli Sacco ( Site 1901)
city: Pisa
country: Italy
facility: AOU Pisana- Ospedale Cisanello ( Site 1905)
city: Tsuchiura
country: Japan
facility: Tsuchiura Beryl Clinic ( Site 2009)
state: Ibaraki
city: Toshimaku
country: Japan
facility: Sekino Hospital ( Site 2016)
state: Tokyo
city: Kumamoto
country: Japan
facility: Kumamoto Chuo Hospital ( Site 2002)
city: Wonju
country: Korea, Republic of
facility: Wonju Severance Christian Hospital-Internal Medicine ( Site 3009)
state: Kang-won-do
city: Gwangju-si
country: Korea, Republic of
facility: Chonnam National University Hospital-Infectious Diseases ( Site 3008)
state: Kwangju-Kwangyokshi
city: Ansan-si
country: Korea, Republic of
facility: Korea University Ansan Hospital ( Site 3007)
state: Kyonggi-do
city: Jinju-si
country: Korea, Republic of
facility: Gyeongsang National University Hospital ( Site 3005)
state: Kyongsangnam-do
city: Pusan
country: Korea, Republic of
facility: Pusan National University Hospital-Internal Medicine ( Site 3010)
state: Pusan-Kwangyokshi
city: Deagu
country: Korea, Republic of
facility: Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 3002)
state: Taegu-Kwangyokshi
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital ( Site 3001)
city: Seoul
country: Korea, Republic of
facility: Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 3003)
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital ( Site 3006)
city: Mexico City
country: Mexico
facility: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran-Departamento de Infectología ( Site 2203)
state: Distrito Federal
city: León
country: Mexico
facility: Morales Vargas Centro de Investigacion ( Site 2206)
state: Guanajuato
city: Guadalajara
country: Mexico
facility: CIO - Centro de Inmuno-Oncología de Occidente ( Site 2207)
state: Jalisco
city: Monterrey
country: Mexico
facility: Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Infectologia ( Site 2204)
state: Nuevo Leon
city: Chihuahua
country: Mexico
facility: ICARO Investigaciones en Medicina ( Site 2200)
city: Veracruz
country: Mexico
facility: Arké SMO S.A de C.V-ARKE SMO S.A. de C.V. ( Site 2210)
city: Christchurch
country: New Zealand
facility: CGM Research Trust ( Site 2307)
state: Canterbury
city: Nelson
country: New Zealand
facility: Pacific Clinical Research Network - Tasman ( Site 2304)
state: Tasman
city: Nawton
country: New Zealand
facility: Lakeland Clinical Trials Waikato ( Site 2302)
state: Waikato
city: Upper Hutt
country: New Zealand
facility: Lakeland Clinical Trials Wellington ( Site 2303)
state: Wellington
city: Auckland
country: New Zealand
facility: Pacific Clinical Research Network West Auckland ( Site 2301)
city: Auckland
country: New Zealand
facility: Optimal Clinical Trials North ( Site 2308)
city: Auckland
country: New Zealand
facility: Optimal Clinical Trials ( Site 2306)
city: Wrocław
country: Poland
facility: Przychodnia EuroMediCare, Wroclaw Lowiecka ( Site 2611)
state: Dolnoslaskie
city: Bydgoszcz
country: Poland
facility: In-Vivo Bydgoszcz ( Site 2601)
state: Kujawsko-pomorskie
city: Krakow
country: Poland
facility: NZOZ GynCentrum - Oddział Kraków ( Site 2609)
state: Malopolskie
city: Bielsko-Biała
country: Poland
facility: NZOZ GynCentrum - Oddział Bielsko-Biała ( Site 2602)
state: Slaskie
city: Katowice
country: Poland
facility: Clinical Medical Research ( Site 2604)
state: Slaskie
city: Katowice
country: Poland
facility: Holsamed ( Site 2603)
state: Slaskie
city: Poznan
country: Poland
facility: PL Certus ( Site 2613)
state: Wielkopolskie
city: Humacao
country: Puerto Rico
facility: Investigadores del Este LLC ( Site 4001)
city: San Juan
country: Puerto Rico
facility: Miralles Clinical Research LLC ( Site 4004)
city: San Juan
country: Puerto Rico
facility: MV HEALTH SERVICES LLC ( Site 4003)
city: București
country: Romania
facility: Spitalul Clinic de Boli Infecțioase și Tropicale Victor Babeș ( Site 2701)
state: Bucuresti
city: Bucuresti
country: Romania
facility: Centrul Medical SANA ( Site 2704)
city: Cluj
country: Romania
facility: Spitalul Clinic de Boli Infecțioase ( Site 2703)
city: Constanta
country: Romania
facility: Spitalul Clinic de Boli Infecțioase ( Site 2702)
city: Elche
country: Spain
facility: Hospital General Universitario de Elche-Infectius Disease ( Site 3105)
state: Alicante
city: Badalona
country: Spain
facility: Hospital Germans Trias i Pujol ( Site 3101)
state: Barcelona
city: Centelles
country: Spain
facility: EAP Osona Sud - Alt Congost S.L.P ( Site 3107)
state: Barcelona
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron ( Site 3102)
state: Cataluna
city: Cartagena
country: Spain
facility: Hospital Santa Lucia-Medicina Infecciosas ( Site 3106)
state: Murcia
city: Barcelona
country: Spain
facility: EAP Sardenya ( Site 3109)
city: Kaoshiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3306)
state: Kaohsiung
city: Taoyuan City
country: Taiwan
facility: Taoyuan General Hospital ( Site 3300)
state: Taoyuan
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Veterans General Hospital ( Site 3307)
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital ( Site 3305)
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital ( Site 3301)
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital ( Site 3304)
city: Taoyuan
country: Taiwan
facility: Chang Gung Memorial Hospital - Linkou Branch ( Site 3303)
city: Bangkok
country: Thailand
facility: Faculty of Medicine Siriraj Hospital-Department of Medicine ( Site 3401)
state: Krung Thep Maha Nakhon
city: Pathumwan
country: Thailand
facility: HIV Netherlands Australia Thailand Research Collaboration ( Site 3402)
state: Krung Thep Maha Nakhon
city: Cherkasy
country: Ukraine
facility: EUROMEDCLINIC ( Site 3517)
state: Cherkaska Oblast
city: Chernivtsi
country: Ukraine
facility: MUNICIPAL NON-PROFIT ENTERPRISE CENTRAL CITY CLINICAL HOSPITAL OF CHERNIVTSI CITY COUNCIL ( Site 3513)
state: Chernihivska Oblast
city: Ivano-Frankivsk
country: Ukraine
facility: Clinical medical and diagnostic center Limited Liability Company "Simedgroup" ( Site 3524)
state: Ivano-Frankivska Oblast
city: Ivano-Frankivsk
country: Ukraine
facility: Regional Phthisiology and Pulmonology Center ( Site 3523)
state: Ivano-Frankivska Oblast
city: Kropyvnytskyi
country: Ukraine
facility: Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 3537)
state: Kirovohradska Oblast
city: Kropyvnytskyi
country: Ukraine
facility: Limited Liability Company Ukrainian Center of Tomotherapy-Clinical Trials Department ( Site 3512)
state: Kirovohradska Oblast
city: Kyiv
country: Ukraine
facility: Medical Center "Harmoniya Krasy" ( Site 3545)
state: Kyivska Oblast
city: Kyiv
country: Ukraine
facility: Edelweiss Medics ( Site 3503)
state: Kyivska Oblast
city: Kyiv
country: Ukraine
facility: Communal Non-Profit Enterprise "Kyiv City Clinical Hospital #1"-Department of Clinical Research ( Site 3514)
state: Kyivska Oblast
city: Kyiv
country: Ukraine
facility: Medbud Clinic-Treatment prevention unit ( Site 3506)
state: Kyivska Oblast
city: Kyiv
country: Ukraine
facility: Medical Center of Limited ( Site 3546)
state: Kyivska Oblast
city: Kyiv
country: Ukraine
facility: Center of Family Medicine Plus ( Site 3502)
state: Kyivska Oblast
city: Lviv
country: Ukraine
facility: Polyclinic of Communal 4th city clinical hospital ( Site 3501)
state: Lvivska Oblast
city: Lviv
country: Ukraine
facility: Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 3525)
state: Lvivska Oblast
city: Lutsk
country: Ukraine
facility: Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 3530)
state: Volynska Oblast
city: Kyiv
country: Ukraine
facility: Medlight Clinic ( Site 3548)
city: Kyiv
country: Ukraine
facility: Kyiv Railway Clinical Hospital No.2 of Branch Health Center -Center of Clinical Trials ( Site 3549)
city: Bristol
country: United Kingdom
facility: Whiteladies Medical Group ( Site 3611)
state: Bristol, City Of
city: Newcastle
country: United Kingdom
facility: Royal Victoria Infirmary ( Site 3608)
state: Newcastle Upon Tyne
city: Oxford
country: United Kingdom
facility: Banbury Cross Health Centre ( Site 3610)
state: Oxfordshire
city: Northamptonshire
country: United Kingdom
facility: Lakeside Surgery ( Site 3600)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: